TRICARE; Coverage of National Cancer Institute (NCI) Sponsored Phase I Studies, 29435-29436 [E9-14441]

Agencies

• Office of the Secretary
• DEPARTMENT OF DEFENSE

[Federal Register Volume 74, Number 118 (Monday, June 22, 2009)]
[Proposed Rules]
[Pages 29435-29436]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-14441]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary

32 CFR Part 199

[DOD-2009-HA-0051]
RIN 0720-AB31


TRICARE; Coverage of National Cancer Institute (NCI) Sponsored 
Phase I Studies

AGENCY: Office of the Secretary, DoD.

ACTION: Proposed rule.

-----------------------------------------------------------------------

SUMMARY: This proposed rule adds coverage of National Cancer Institute 
(NCI) sponsored Phase I studies for certain beneficiaries. The NCI 
sponsored clinical treatment trials are conducted in a series of steps 
called phases. Phase I trials are the first studies conducted in 
people. They evaluate how a new drug should be given (by mouth, 
injected into the blood, or injected into the muscle), how often, and 
what dose is safe.

DATES: Written comments received at the address indicated below by 
August 21, 2009 will be accepted.

ADDRESSES: You may submit comments, identified by docket number and/or 
Regulatory Information Number (RIN) number and title, by either of the 
following methods:
     Federal Rulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Federal Docket Management System Office, 1160 
Defense Pentagon, Washington, DC 20301-1160.
    Instructions: All submissions received must include the agency name 
and docket number or RIN for this Federal Register document. The 
general policy for comments and other submissions from members of the 
public is to make these submissions available for public viewing on the 
Internet at https://www.regulations.gov as they are received without 
change, including any personal identifiers or contact information.

FOR FURTHER INFORMATION CONTACT: Colonel John Kugler, TRICARE 
Management Activity, Office of the Chief Medical Officer, telephone 
(703) 681-0064.

SUPPLEMENTARY INFORMATION: This proposed rule adds the coverage of a 
subset of National Cancer Institute (NCI) sponsored Phase I trials for 
certain TRICARE patients. The NCI sponsored clinical treatment trials 
are conducted in a series of steps called phases. Phase I trials are 
the first studies conducted in people. They evaluate how a new drug 
should be given (by mouth, injected into the blood, or injected into 
the muscle), how often, and what dose is safe. A Phase I trial usually 
enrolls only a small number of patients, sometimes as few as a dozen. A 
Phase II trial continues to test the safety of the drug, and begins to 
evaluate how well the new drug works. Phase II studies usually focus on 
a particular type of cancer. A Phase III trial tests a new drug, a new 
combination of drugs, or a new surgical procedure in comparison to the 
current standard. A participant will usually be assigned to the 
standard group or the new group at random. Phase III trials often 
enroll large numbers of people and may be conducted at many doctors' 
offices, clinics, and cancer centers nationwide.
    This proposed rule adds coverage only of NCI sponsored Phase I 
trials with clinical or preclinical data providing a reasonable 
expectation that the treatment will be at least as effective as the 
non-investigational alternative. Additionally, only those TRICARE 
patients for whom standard treatment has been or would be ineffective, 
does not exist, or there is no superior non-investigational treatment 
alternative, would be eligible for these additional trials. TRICARE has 
covered NCI sponsored Phase II and III trials since 1996. The NCI 
estimates that Phase I trial participants represent about 3.4 percent 
of overall Phase II and III participants combined. Based on the history 
of DoD participation in these studies, it is estimated that there would 
be a maximum of one thousand new patients annually enrolling in Phase I 
trials. It is estimated that the net cost to TRICARE of adding Phase I 
treatment trials will increase costs by 12.8 percent of the total gross 
costs (approximately $150,000 in FY09). Currently ten states mandate 
coverage of at least some Phase I trials.

Regulatory Procedures

Executive Order 12866, ``Regulatory Planning and Review''

    Section 801 of title 5, United States Code (U.S.C.), and Executive 
Order (E.O.) 12866 requires certain regulatory assessments and 
procedures for any major rule or significant regulatory action, defined 
as one that would result in an annual effect of $100 million or more on 
the national economy or which would have other substantial impacts. It 
has been certified that this rule is not an economically significant 
rule, however, it is a regulatory action which has been reviewed by the 
Office of Management and Budget as required under the provisions of 
E.O. 12866.

Sec. 202, Public Law 104-4, ``Unfunded Mandates Reform Act''

    It has been certified that this rule does not contain a Federal 
mandate that may result in the expenditure by State, local and tribal 
governments, in aggregate, or by the private sector, of $100 million or 
more in any one year.

Public Law 96-354, ``Regulatory Flexibility Act'' (5 U.S.C. 601)

    The Regulatory Flexibility Act (RFA) requires each Federal agency 
prepare, and make available for public comment, a regulatory 
flexibility analysis when the agency issues a regulation which would 
have a significant impact on a substantial number of small entities. 
This proposed rule will not significantly affect a substantial number 
of small entities for purposes of the RFA.

Public Law 96-511, ``Paperwork Reduction Act'' (44 U.S.C. Chapter 35)

    This rule will not impose additional information collection 
requirements on the public under the Paperwork Reduction Act of 1995 
(44 U.S.C. 3501-3511).

Executive Order 13132, ``Federalism''

    This proposed rule has been examined for its impact under E.O. 
13132 and it does not contain policies that have federalism 
implications that would have substantial direct effects on the States, 
on the relationship between the national government and the States, or 
on the distribution of power and responsibilities among the various 
levels of government; therefore, consultation with State and local 
officials is not required.

List of Subjects in 32 CFR Part 199

    Claims, Dental health, Health care, Health insurance, Individuals 
with disabilities, Military personnel.

    Accordingly, 32 CFR Part 199 is proposed to be amended as follows:

PART 199--[AMENDED]

    1. The authority citation for Part 199 continues to read as 
follows:

    Authority:  5 U.S.C. 301; 10 U.S.C. Chapter 55.

    2. Section 199.4 is amended by:

[[Page 29436]]

    A. Redesignating paragraphs (e)(26)(ii)(B)(2), (3) and (4) as 
paragraphs (e)(26)(ii)(B)(3), (4) and (5);
    B. Adding a sentence to the end of the introductory text in 
paragraph (e)(26)(ii)(B);
    C. Revising paragraph (e)(26)(ii)(B)(1)(ii);
    D. Revising paragraph (e)(26)(ii)(B)(1)(iv);
    E. Adding new paragraph (e)(26)(ii)(B)(1)(v); and
    F. Adding a new paragraph (e)(26)(ii)(B)(2) to read as follows:


Sec.  199.4  Basic program benefits.

* * * * *
    (e) * * *
    (26) * * *
    (ii) * * *
    (B) * * * Additionally, Phase I studies may be approved on a case 
by case basis when the requirements below are met.
    (1) * * *
    (ii) Such treatments are NCI sponsored Phase I, Phase II or Phase 
III protocols; and
* * * * *
    (iv) The institutional and individual providers are CHAMPUS 
authorized providers; and,
    (v) The requirements for Phase I protocols in paragraph 
(e)(26)(ii)(B)(2) of this section are met:
    (2) Requirements for Phase I protocols are:
    (i) Standard treatment has been or would be ineffective, does not 
exist, or there is no superior non-investigational treatment 
alternative; and,
    (ii) The available clinical or preclinical data provide a 
reasonable expectation that the treatment will be at least as effective 
as the non-investigational alternative; and,
    (iii) The facility and personnel providing the treatment are 
capable of doing so by virtue of their experience, training, and volume 
of patients treated to maintain expertise; and,
    (iv) The referring physician has concluded that the enrollee's 
participation in such a trial would be appropriate based upon the 
satisfaction of paragraphs (e)(26)(ii)(B)(2)(i) through 
(e)(26)(ii)(B)(2)(iii) of this section.
* * * * *

    Dated: May 15, 2009.
Patricia Toppings,
OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. E9-14441 Filed 6-19-09; 8:45 am]
BILLING CODE 5001-06-P